M&A / Deals Obesity biotech Kailera’s record-breaking IPO PharmaphorumWhen Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge - and that expectation has now been fulfilled.M&A / DealsRead full story pharminent April 17, 2026 (Last updated: April 17, 2026) Pharmaphorum When Kailera revealed its plans for an IPO last month, there was a feeling that it could be huge – and that expectation has now been fulfilled. M&A / DealsRead full story Post navigation Previous: S16 Ep53: Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck – Post-CRT Decisions in the Locally Advanced SettingNext: Lilly’s Foundayo reaches 1,390 patients in first week, trailing Novo’s oral Wegovy launch Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
